Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models. European early-phase trials of the combination in patients with metastatic colorectal cancer indicate good response rates across doses tested and manageable toxicities, with available data supporting use of a regimen of oral capecitabine at 1,000 mg/m2 twice daily on days 1 to 14 plus IV irinotecan at 250 mg/m2 on day 1 every 21 days in this setting. The European Organisation for Research and Treatment of Cancer has planned a phase III trial (EORTC 40015) comparing this regimen of capecitabine/irinotecan with infusional fluorouracil (5-FU)/leucovorin plus irinotecan in approximately 700 patients with metastatic colorectal cancer. The QUASAR (Quick and Simple and Reliable) 2 adjuvant trial will compare 5-FU/leucovorin with capecitabine/irinotecan given over 6 months as adjuvant therapy in patients with stage II/III colorectal cancer. These trials will help define the roles of this combination in the treatment of colorectal cancer.

Type

Journal article

Journal

Oncology (Williston Park)

Publication Date

12/2002

Volume

16

Pages

12 - 15

Keywords

Administration, Oral, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Capecitabine, Clinical Trials as Topic, Colorectal Neoplasms, Deoxycytidine, Dose-Response Relationship, Drug, Europe, Fluorouracil, Humans, Infusions, Intravenous, Leucovorin, Multicenter Studies as Topic, Randomized Controlled Trials as Topic